{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:15:19Z","timestamp":1747149319966,"version":"3.40.5"},"reference-count":7,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:00:00Z","timestamp":1693699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["IJU Case Reports"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Pembrolizumab administration has become the standard of care for patients with urothelial carcinoma, though a variety of adverse events have been reported. Presented here is a rare case of pancreatitis that occurred as an immune\u2010related adverse event.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>An 81\u2010year\u2010old man undergoing treatment with pembrolizumab for multiple lung metastases from renal pelvic cancer was presented with a fever and diagnosed with pancreatitis based on elevated pancreatic enzyme levels and imaging findings. There was no history of alcohol consumption or findings indicating gallstones, elevated liver enzymes, or abdominal complications. The patient was diagnosed with immune\u2010related adverse event pancreatitis and treated with Lactate Ringer's solution (3000\u2009mL\/day) and steroids, during which his condition improved.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although pancreatitis is a rare complication, it should always be considered as a potential immune\u2010related adverse event in patients treated with an immune checkpoint inhibitor such as pembrolizumab.<\/jats:p><\/jats:sec>","DOI":"10.1002\/iju5.12633","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T03:39:10Z","timestamp":1693798750000},"page":"402-405","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pancreatitis as immune\u2010related adverse event during pembrolizumab therapy for multiple lung metastases from renal pelvic cancer"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1043-1387","authenticated-orcid":false,"given":"Kazuki","family":"Kokura","sequence":"first","affiliation":[{"name":"Toyooka Hospital  Toyooka Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Toyooka Hospital  Toyooka Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Takuma","sequence":"additional","affiliation":[{"name":"Toyooka Hospital  Toyooka Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Yokozeki","sequence":"additional","affiliation":[{"name":"Toyooka Hospital  Toyooka Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6529-0526","authenticated-orcid":false,"given":"Shoko","family":"Uketa","sequence":"additional","affiliation":[{"name":"Toyooka Hospital  Toyooka Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Uemura","sequence":"additional","affiliation":[{"name":"Toyooka Hospital  Toyooka Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,9,3]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2019.04.015"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0502-7"},{"key":"e_1_2_13_4_1","unstructured":"National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) management of immunotherapy\u2010related toxicities: version 2.2023. [Cited 15 Jun 2023.] Available from URL:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf."},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109250"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000202"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.7366-21"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.02.006"}],"container-title":["IJU Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iju5.12633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T20:34:44Z","timestamp":1700080484000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iju5.12633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,3]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1002\/iju5.12633"],"URL":"https:\/\/doi.org\/10.1002\/iju5.12633","archive":["Portico"],"relation":{},"ISSN":["2577-171X","2577-171X"],"issn-type":[{"type":"print","value":"2577-171X"},{"type":"electronic","value":"2577-171X"}],"subject":[],"published":{"date-parts":[[2023,9,3]]},"assertion":[{"value":"2023-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}